SCHEMBL2769682

SCHEMBL2769682

CCOC(=O)Cc1c(C)c(Sc2ccc(S(C)(=O)=O)cc2)n2ccccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PTGDR2 Q9Y5Y4 2/20 0.41
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 3/20 0.39
LMNA P02545 2/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39
GAA P10253 3/20 0.38
PTGS2 P35354 2/20 0.38
GLA P06280 1/20 0.38
HPGD P15428 1/20 0.38
PTGS1 P23219 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
IDO1 P14902 1/20 0.37
MAPK1 P28482 1/20 0.37
HBB P68871 1/20 0.37
HIF1A Q16665 1/20 0.37
RXFP1 Q9HBX9 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2769298 0.87 PTGDR2 (0.52) PTGDR2PTGS2
SCHEMBL2772075 0.83 PTGDR2 (0.38) PTGDR2ALDH1A1KDM4ELMNATSHR
SCHEMBL2774837 0.83 PTGDR2 (0.40) PTGDR2ALDH1A1PTGS2PTGS1CYP1A2
SCHEMBL2770081 0.82 PTGDR2 (0.46) PTGDR2ALDH1A1KDM4ELMNATSHR
SCHEMBL2769893 0.82 PTGDR2 (0.44) L3MBTL1SMN1; SMN2PTGDR2ALDH1A1KDM4E
SCHEMBL4636923 0.82 L3MBTL1 (0.51) L3MBTL1SMN1; SMN2PTGDR2ALDH1A1KDM4E
SCHEMBL3568010 0.79 PTGDR2 (0.47) PTGDR2ALDH1A1PTGS2PTGS1
SCHEMBL2770749 0.77 PTGDR2 (0.42) L3MBTL1SMN1; SMN2PTGDR2PTGS2PTGS1
SCHEMBL2769429 0.77 EGFR (0.43) L3MBTL1SMN1; SMN2PTGDR2ALDH1A1KDM4E
SCHEMBL2769329 0.76 SMN1; SMN2 (0.42) L3MBTL1SMN1; SMN2ALDH1A1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1910357-B1 INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS ARGENTA DISCOVERY LTD (GB) 2010-04-14 EP disclosed
US-20090163534-A1 Indolizine Derivatives ARGENTA DISCOVERY LIMITED (GB) 2009-06-25 US disclosed
EP-1910357-A2 INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS Argenta Discovery Limited (GB) 2008-04-16 EP disclosed
WO-2006136859-A2 INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS ARGENTA DISCOVERY LIMITED (GB) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163534-A1 Indolizine Derivatives HRH4, HRH2, NR1H2 L3MBTL1 3345/4885SMN1; SMN2 3306/4885PTGDR2 363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.